S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Is New IPO Instacart Already Hitting Speed Bumps?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Is New IPO Instacart Already Hitting Speed Bumps?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Is New IPO Instacart Already Hitting Speed Bumps?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Is New IPO Instacart Already Hitting Speed Bumps?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
NASDAQ:EOLS

Evolus (EOLS) Stock Forecast, Price & News

$9.19
+0.04 (+0.44%)
(As of 09/22/2023 ET)
Compare
Today's Range
$9.14
$9.26
50-Day Range
$7.21
$10.20
52-Week Range
$6.51
$11.49
Volume
233,859 shs
Average Volume
356,700 shs
Market Capitalization
$523.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.40

Evolus MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
132.9% Upside
$21.40 Price Target
Short Interest
Bearish
8.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.27
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$1.30 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.76) to ($0.51) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

347th out of 965 stocks

Pharmaceutical Preparations Industry

147th out of 455 stocks


EOLS stock logo

About Evolus (NASDAQ:EOLS) Stock

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It serves self-pay aesthetic healthcare market. Evolus, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.

EOLS Price History

EOLS Stock News Headlines

Evolus: Gaining Market Share
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Evolus to Participate in September Conferences
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Insider Spends US$1.3m Buying More Shares In Evolus
Evolus Director Trades $1.30M In Company Stock
Barclays Reaffirms Their Hold Rating on Evolus (EOLS)
Evolus (EOLS) Receives a Buy from Mizuho Securities
5 Analysts Have This to Say About Evolus
Why Shares of Evolus Are Jumping Thursday
See More Headlines
Receive EOLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter.

EOLS Company Calendar

Last Earnings
8/02/2023
Today
9/22/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EOLS
Fax
N/A
Employees
215
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.40
High Stock Price Forecast
$27.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+132.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-74,410,000.00
Pretax Margin
-39.29%

Debt

Sales & Book Value

Annual Sales
$148.62 million
Book Value
$0.33 per share

Miscellaneous

Free Float
53,896,000
Market Cap
$523.55 million
Optionable
Optionable
Beta
1.60
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. David MoatazediMr. David Moatazedi (Age 45)
    Pres, CEO & Director
    Comp: $1.27M
  • Ms. Sandra Beaver (Age 45)
    Chief Financial Officer
    Comp: $372.23k
  • Dr. Rui Avelar C.CFP (Age 61)
    Dip.SportMed, M.D., Chief Medical Officer and Head of R&D
    Comp: $682.03k
  • Mr. David K. Erickson
    VP of Investor Relations
  • Mr. Jeffrey J. Plumer
    Gen. Counsel
  • Mr. Kurt Knab
    VP of Sales
  • Ms. Tomoko Yamagishi-Dressler
    Chief Marketing Officer
  • Ms. Jessica Novak
    Sr. VP of HR













EOLS Stock - Frequently Asked Questions

Should I buy or sell Evolus stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EOLS shares.
View EOLS analyst ratings
or view top-rated stocks.

What is Evolus' stock price forecast for 2023?

4 Wall Street analysts have issued twelve-month price objectives for Evolus' shares. Their EOLS share price forecasts range from $18.00 to $27.00. On average, they predict the company's stock price to reach $21.40 in the next year. This suggests a possible upside of 132.9% from the stock's current price.
View analysts price targets for EOLS
or view top-rated stocks among Wall Street analysts.

How have EOLS shares performed in 2023?

Evolus' stock was trading at $7.51 at the beginning of 2023. Since then, EOLS shares have increased by 22.4% and is now trading at $9.19.
View the best growth stocks for 2023 here
.

When is Evolus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our EOLS earnings forecast
.

How were Evolus' earnings last quarter?

Evolus, Inc. (NASDAQ:EOLS) announced its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.02. The company earned $49.35 million during the quarter, compared to analysts' expectations of $46.12 million. Evolus had a negative trailing twelve-month return on equity of 507.42% and a negative net margin of 39.36%.

What guidance has Evolus issued on next quarter's earnings?

Evolus updated its FY 2023 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $185.00 million-$195.00 million, compared to the consensus revenue estimate of $187.83 million.

What is David Moatazedi's approval rating as Evolus' CEO?

1 employees have rated Evolus Chief Executive Officer David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among the company's employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Evolus own?
When did Evolus IPO?

(EOLS) raised $65 million in an IPO on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

What is Evolus' stock symbol?

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Who are Evolus' major shareholders?

Evolus' stock is owned by many different retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (7.91%), BlackRock Inc. (5.26%), Great Point Partners LLC (4.27%), Schroder Investment Management Group (2.87%), Boothbay Fund Management LLC (2.29%) and Marshall Wace LLP (1.82%). Insiders that own company stock include Alphaeon 1 Llc, Crystal Muilenburg, David Moatazedi, David N Gill, Lauren P Silvernail, Medytox Inc, Robert Hayman, Rui Avelar, Sandra Beaver and Vikram Malik.
View institutional ownership trends
.

How do I buy shares of Evolus?

Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evolus' stock price today?

One share of EOLS stock can currently be purchased for approximately $9.19.

How much money does Evolus make?

Evolus (NASDAQ:EOLS) has a market capitalization of $523.55 million and generates $148.62 million in revenue each year. The company earns $-74,410,000.00 in net income (profit) each year or ($1.17) on an earnings per share basis.

How many employees does Evolus have?

The company employs 215 workers across the globe.

How can I contact Evolus?

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The official website for the company is www.evolus.com. The company can be reached via phone at (949) 284-4555 or via email at ir@evolus.com.

This page (NASDAQ:EOLS) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -